Avillion adds Ted W. Love to board

Avillion LLP, which focuses on clinical co-development of therapeutics, today announced that Ted W. Love, M.D has been appointed a non-executive director of the business.

Vastly-experienced, Dr Love was most recently the Executive Vice-President of Research and Development at Onyx Pharmaceuticals, overseeing the successful approval of Kyprolis. Prior to that, he was Chairman and Chief Executive Officer of Nuvelo, Inc., a biopharmaceutical company from March 2001 to January 2009, having been appointed President and Chief Operating Officer in January 2001.

Dr Love joined Nuvelo from Theravance, where he served as Senior Vice President of Development from 1998 until 2001, and before that he spent six years at Genetech, Inc., holding a number of senior management positions in medical affairs and product development.

Lewis Cameron, CEO of Avillion, commented: “To have someone of Dr Love’s calibre and experience on our board is a fantastic coup for Avillion. We’re sure he’ll use his insight, contacts and knowledge to the best interests of the company and will complement other board members’ specialisms perfectly. It’s great to have Dr Love on board, and we can’t wait to start working with him.

Dr. Love serves as a director of several companies including Santarus Inc., Mast Therapeutics, Amicus Therapeutics and KaloBios Inc. He also served on the 29-member California Independent Citizen's Oversight Commission, which oversees the $3 billion allocated to stem cell research authorized by California Proposition 71.

Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed his internal medicine and cardiovascular fellowship training at Massachusetts General Hospital and Harvard Medical School.

Download press release

File: pdf | Size: 89 KB